Oncotarget

Research Papers:

Identification of LRP-1 as an endocytosis and recycling receptor for β1-integrin in thyroid cancer cells

Louis Theret, Albin Jeanne, Benoit Langlois, Cathy Hachet, Marion David, Michel Khrestchatisky, Jérôme Devy, Emonard Hervé, Sébastien Almagro and Stéphane Dedieu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:78614-78632. https://doi.org/10.18632/oncotarget.20201

Metrics: PDF 1286 views  |   HTML 2446 views  |   ?  


Abstract

Louis Theret1,2, Albin Jeanne1,2,3, Benoit Langlois1,2, Cathy Hachet1,2, Marion David4, Michel Khrestchatisky5, Jérôme Devy1,2, Emonard Hervé1,2, Sébastien Almagro1,2 and Stéphane Dedieu1,2

1Université de Reims Champagne-Ardenne, UFR Sciences Exactes et Naturelles, Reims, France

2CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire, MEDyC, Reims, France

3SATT Nord, Lille, France

4VECT-HORUS SAS, Faculté de Médecine Secteur Nord, Marseille, France

5Aix Marseille Université, CNRS, NICN, Marseille, France

Correspondence to:

Stéphane Dedieu, email: stephane.dedieu@univ-reims.fr

Keywords: LRP-1, β1-integrin, cancer, endocytosis, recycling

Received: March 31, 2017    Accepted: July 25, 2017    Published: August 10, 2017

ABSTRACT

LRP-1 is a large endocytic receptor mediating the clearance of various molecules from the extracellular matrix. LRP-1 was reported to control focal adhesion turnover to optimize the adhesion-deadhesion balance to support invasion. To better understand how LRP-1 coordinates cell-extracellular matrix interface, we explored its ability to regulate cell surface integrins in thyroid carcinomas. Using an antibody approach, we demonstrated that β1-integrin levels were increased at the plasma membrane under LRP1 silencing or upon RAP treatment, used as LRP-1 antagonist. Our data revealed that LRP-1 binds with both inactive and active β1-integrin conformations and identified the extracellular ligand-binding domains II or IV of LRP-1 as sufficient to bind β1-integrin. Using a recombinant β1-integrin, we demonstrated that LRP-1 acts as a regulator of β1-integrin intracellular traffic. Moreover, RAP or LRP-1 blocking antibodies decreased up to 36% the number of β1-integrin-containing endosomes. LRP-1 blockade did not significantly affect the levels of β1-integrin-containing lysosomes while decreasing localization of β1-integrin within Rab-11 positive vesicles. Overall, we identified an original molecular process in which LRP-1 acts as a main regulator of β1-integrin internalization and recycling in thyroid cancer cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20201